Context Therapeutics Receives FDA Fast Track Designation for CTIM-76 in Platinum-Resistant Ovarian Cancer
Key Insights
Context Therapeutics received FDA Fast Track Designation for CTIM-76, a CLDN6 (search) x CD3 (search) T cell engaging bispecific antibody, for treating platinum-resistant ovarian cancer (search) in patients who have exhausted standard therapies.
The company is currently conducting a Phase 1 clinical trial evaluating CTIM-76's safety and efficacy in patients with CLDN6 (search)-positive advanced or metastatic ovarian, endometrial and testicular cancers.
Interim data from the ongoing Phase 1a trial is expected to be released in June 2026, marking a key milestone for the drug's development.
Context Therapeutics Inc. (Nasdaq: CNTX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to CTIM-76, a CLDN6 (search) x CD3 (search) T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer (search) in patients who have received all standard of care therapies. The designation highlights the potential of CTIM-76 to address a significant unmet medical need in this patient population.
Clinical Development Program
Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to assess the safety and efficacy of the drug in subjects with CLDN6 (search)-positive advanced or metastatic ovarian, endometrial and testicular cancers. The study includes both dose escalation and dose expansion portions that will evaluate safety, tolerability and pharmacokinetics, as well as anti-tumor activity measured by overall response rate, duration of response and disease control rate.
The company expects to share interim data from the Phase 1a trial in June 2026, representing a key milestone in the drug's clinical development timeline.
Mechanism of Action and Target Profile
CTIM-76 is a CLDN6 (search) x CD3 (search) T cell engaging bispecific antibody that targets Claudin 6 (search) (CLDN6), a protein enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric and testicular cancers. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.
Regulatory Significance
"We are pleased to receive Fast Track Designation for CTIM-76, which underscores its potential to improve the lives of patients with platinum-resistant ovarian cancer (search)," said Karen Chagin, M.D., Chief Medical Officer of Context. "This designation is an important step forward in our goal to quickly and efficiently advance CTIM-76 through clinical development and we look forward to sharing interim data for this program in June 2026."
The FDA's Fast Track Designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas of unmet need.
Company Pipeline
Context Therapeutics is a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors. The company's goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76 (Claudin 6 (search) x CD3 (search) TCE), CT-95 (Mesothelin x CD3 TCE), and CT-202 (Nectin-4 (search) x CD3 TCE). The company is headquartered in Philadelphia.
More information about the CTIM-76 clinical trial (NCT06515613) can be found on clinicaltrials.gov.